BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8867429)

  • 1. [New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)].
    Reimer P; Tombach B; Daldrup H; Hesse T; Sander G; Balzer T; Shamsi K; Berns T; Rummeny EJ; Peters PE
    Radiologe; 1996 Feb; 36(2):124-33. PubMed ID: 8867429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.
    Mintorovitch J; Shamsi K
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 3):37-40. PubMed ID: 10887650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
    Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
    Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging.
    Reimer P; Rummeny EJ; Daldrup HE; Hesse T; Balzer T; Tombach B; Peters PE
    Eur Radiol; 1997; 7(2):275-80. PubMed ID: 9038130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume.
    Reimer P; Schuierer G; Balzer T; Peters PE
    Magn Reson Med; 1995 Nov; 34(5):694-7. PubMed ID: 8544689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
    Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R
    Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal nodular hyperplasia of the liver: serial MRI with Gd-DOTA, superparamagnetic iron oxide, and Gd-EOB-DTPA.
    Kacl GM; Hagspiel KD; Marincek B
    Abdom Imaging; 1997; 22(3):264-7. PubMed ID: 9107647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
    Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
    Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging.
    Shamsi K; Balzer T; Saini S; Ros PR; Nelson RC; Carter EC; Tollerfield S; Niendorf HP
    Radiology; 1998 Feb; 206(2):365-71. PubMed ID: 9457187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of focal hepatic masses by dynamic contrast-enhanced MR imaging: findings in 311 lesions.
    Quillin SP; Atilla S; Brown JJ; Borrello JA; Yu CY; Pilgram TK
    Magn Reson Imaging; 1997; 15(3):275-85. PubMed ID: 9201674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions.
    Vogl TJ; Hammerstingl R; Schwarz W; Mack MG; Müller PK; Pegios W; Keck H; Eibl-Eibesfeldt A; Hoelzl J; Woessmer B; Bergman C; Felix R
    Radiology; 1996 Mar; 198(3):881-7. PubMed ID: 8628887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of liver lesions with gadolinium-enhanced VIBE sequence in comparison with SPIO-enhanced MRI].
    Heim P; Steiner P; Schoder V; Dieckmann C; Kuhlencordt R; Adam G
    Rofo; 2003 Oct; 175(10):1376-83. PubMed ID: 14556107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents.
    Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM
    Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [T1-weighted dynamic MRI with new superparamagnetic iron oxide particles (Resovist): results of a phantom study as well as 25 patients].
    Müller M; Reimer P; Wiedermann D; Allkemper T; Marx C; Tombach B; Rummeny EJ; Shamsi K; Balzer T; Peters PE
    Rofo; 1998 Mar; 168(3):228-36. PubMed ID: 9551108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-enhanced MR imaging of the liver.
    Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
    J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New super-paramagnetic iron particles for MRI. Phase II study of malignant liver tumors].
    Daldrup HE; Reimer P; Rummeny EJ; Tombach B; Berns T; Balzer T; Schimpfky C; Peters PE
    Radiologe; 1995 Aug; 35(8):486-93. PubMed ID: 7568792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferumoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging.
    Takahama K; Amano Y; Hayashi H; Ishihara M; Kumazaki T
    Abdom Imaging; 2003; 28(4):525-30. PubMed ID: 14580096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.